European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 541-545 , June 2010

Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: A word of caution for oral surgeons and oncologists

  • P. Chaturvedi

      Affiliations

    • Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, India
    • Corresponding Author InformationCorresponding author. Department of Surgical Oncology, Tata Memorial Hospital, EB Road, Parel, Mumbai, Maharshtra 400 012, India. Fax: +91 22 2414 6937.
    • ,
  • P.S. Pai

      Affiliations

    • Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, India
    • ,
  • D.A. Chaukar

      Affiliations

    • Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, India
    • ,
  • S. Gupta

      Affiliations

    • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
    • ,
  • A.K. D'cruz

      Affiliations

    • Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, India

,Accepted 7 December 2009.

References 

  1. Ruggiero SL, Mehrotra B, Rosenberg TJ. Osteonecrosis of the jaws associated with the use of bisphosphonates; a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  2. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Int Med. 2006;144:753–761
  3. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488–493
  4. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335:1785–1791
  5. Glass DA, Patel MS, Karsenty G. A new insight into the formation of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2479–2480
  6. Ruggiero S, Gralow J, Marx R, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7–14
  7. Bannias A, Kastritis E, Bannia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2006;23:8580–8587
  8. Badros A, Weikei D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945–952
  9. Pozzi S, Marcheselli R, Sacchi S, et al. Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood. 2005;106:5057a
  10. Durie GM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates (correspondence). N Engl J Med. 2005;3531:99–102
  11. Tosi P, Zamagni E, Cangini D, et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogenous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood. 2005;106:3461a
  12. Mehrotra B. Safety profile of intravenous bisphosphonates. Semin Oncol. 2007 Dec;34(Suppl. 4):S24–S27
  13. Lacy M, Dispenzieri A, Gertz M, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047–1053
  14. Thakkar S, Isada C, Smith J, et al. Jaw complications associated with bisphosphonates use in patients with plasma cell dyscrasias. Med Oncol. 2006;23:51–56
  15. Rosen LS, Gordon D, Kaminski M, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003;98:1735–1744

PII: S0748-7983(09)00544-7

doi: 10.1016/j.ejso.2009.12.003

European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 541-545 , June 2010

Article Tools

* Image Usage & Resolution